NCT02950766: what clinicians are saying
NeoVax plus ipilimumab; NeoVax in high-risk renal cell carcinoma · NCT02950766 ↗ · Phase 1 · Patrick Ott, MD, PhD
The clinicians cited see NCT02950766 as support for pursuing personalized vaccination, pointing to tumor-directed immune responses, but a medical oncologist interprets the findings more definitively as showing clinical benefit. Another medical oncologist judges tolerability favorably, alongside a relayed patient experience describing treatment as difficult at times. Comparative benefit and uncommon harms remain beyond what the sources reviewed for this edition can establish.
Created with AI · how we check it
- edition 1
- commentary checked Nov 21, 2026
- 115 verified statements
This edition $750, with MCP access for your AI agent. Get this report
9 findings, and what sits behind each
01. Adjuvant RCC vaccine: most speakers welcome it, and most highlight efficacy
5 of the report's 13 cited clinicians · 11 statements from 7 speakers in 9 sources · 12 passages
Limitations recorded: 3.
Draws on: Secondary endpoint: Number of participants with NeoVax induced IFN γ (interferon γ) T-cell Response against neoepitopes measured by ELISPOT at week 16, Population and setting, Safety and tolerability.
02. RCC vaccines: how most clinicians distinguish neoantigen targeting from older approaches
3 of the report's 13 cited clinicians · 13 statements from 3 speakers in 5 sources, 2 of them podcasts or videos · 9 passages
Limitations recorded: 3.
Draws on: The comparison, Design and conduct, Secondary endpoint: Number of participants with NeoVax induced IFN γ (interferon γ) T-cell Response against neoepitopes measured by ELISPOT at week 16, Population and setting, Safety and tolerability.
03. Adjuvant RCC vaccination: what clinicians highlight about the toxicity burden
2 of the report's 13 cited clinicians · 7 statements from 2 speakers in 4 sources, 1 of them a podcast or video · 5 passages
Limitations recorded: 3.
Draws on: Safety and tolerability, Secondary endpoint: Number of participants with NeoVax induced IFN γ (interferon γ) T-cell Response against neoepitopes measured by ELISPOT at week 16, Population and setting.
04. RCC protein vaccines: clinicians see feasibility but one flags complexity
2 of the report's 13 cited clinicians · 6 statements from 2 speakers in 3 sources, 1 of them a podcast or video · 4 passages
Limitations recorded: 2.
Draws on: Secondary endpoint: Number of participants with NeoVax induced IFN γ (interferon γ) T-cell Response against neoepitopes measured by ELISPOT at week 16, Population and setting, The comparison, Safety and tolerability, Design and conduct.
05. RCC vaccine research: why most speakers fear political and funding threats
No named clinician · accounts and unnamed speakers · 7 statements from 5 speakers in 1 source · 9 passages
Limitations recorded: 3.
06. RCC vaccines: a speaker favors affordability, offers trial help if wanted
No named clinician · accounts and unnamed speakers · 4 statements from 1 speaker in 1 source · 6 passages
Limitations recorded: 3.
Beyond the trial population
07. RCC vaccines: why clinicians look to randomized testing with adjuvant pembrolizumab
2 of the report's 13 cited clinicians · 7 statements from 2 speakers in 3 sources, 1 of them a podcast or video · 4 passages
Limitations recorded: 3.
08. RCC vaccination after surgery: what speakers say
1 of the report's 13 cited clinicians · 5 statements from 1 speaker in 2 sources, 1 of them a podcast or video · 3 passages
Limitations recorded: 3.
09. Non-clear-cell RCC: why a speaker flags uncertainty about vaccine-trial inclusion
No named clinician · accounts and unnamed speakers · 2 statements in 2 sources · 2 passages
Limitations recorded: 2.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it. Select a part of the trial to see which findings draw on it.
- Finding 1 of 9
5 of the report's 13 cited clinicians
Adjuvant RCC vaccine: most speakers welcome it, and most highlight efficacy
11 statements from 7 speakers in 9 sources
6 of the 7 named speakers in this finding hold this view; 5 of the 7 hold its caveat, “most highlight efficacy”
- 11
- statements
- 12
- passages
- 9
- sources
- 7
- speakers
What the statements areViews 7Questions and uncertainty 1Clinical experience 0Comparisons 0Restated results and context 3Statement-to-passage links (a passage can back several statements)Supporting a statement 14Giving context 1Recorded with the findingLimitations: 3
8 posts and articles · 1 publication
Draws on: Secondary endpoint: Number of participants with NeoVax induced IFN γ (interferon γ) T-cell Response against neoepitopes measured by ELISPOT at week 16, Population and setting, Safety and tolerability.
- Beyond the trial population
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap: one statement can back several findings.
3 of the 9 findings and 12 of the 115 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.
Abbreviations (5)
DLT, dose-limiting toxicity; HCP, healthcare professional; MCP, Model Context Protocol, how AI agents read the report; NPI, National Provider Identifier, the US registry number for clinicians; RCC, renal cell carcinoma.
The full NCT02950766 report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified statements, each linked to the original. One report in the catalog, IDeate-Lung01, is free in full, so you can see what a paid report holds before you buy: read the free IDeate-Lung01 report.
By the numbers
- 37commentary sources screened
- 24sources cited by verified statements
- 22named in screened sources
- 22speakers cited in the report
- 15cited speakers with a verified identity
13 cited clinicians, speakers with a confirmed clinical role, of them 13 physicians. By role and specialty:
- 7 physician, Medical oncology
- 4 physician, specialty not confirmed
- 1 physician, Cardiology
- 1 physician, Radiation oncology
Also in the sources: 2 organizational or shared accounts, not counted as people.
- 115verified statements, each linked to its source
- 40of them from speakers with a confirmed clinical role
- 9findings
Built by AI from public clinician commentary, checked by automated review; every statement links to its source.
A cited clinician is a cited speaker whose clinical role the NPI registry or their own institution's staff page confirms; a role a source only states is not counted. A verified identity says who a speaker is, with or without such a role. Physicians are clinicians whose confirmed role is a physician's.
Counts show what the report kept, not how many clinicians hold a view. Size is set by the verified statements; Standard and Deep need 5 or more cited clinicians. Statements from sponsors, hosts and organisations are labelled and count apart.
What's inside
| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 9 | Titles free |
| Detailed analysis | 11 sections | Paid |
| Verified statements with short source quotes and links | 115 | Paid |
| Who said each statement: the cited speakers | 22 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 13 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 15 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 15 | Free |
| Sources with links | 24 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |
Every edition names who said each statement, with MCP access for your AI agent. Each verified speaker comes with their verified IDs (NPI, ORCID, staff page) so your team can check each attribution. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
Trial aspects
13 discussed · 2 no commentary found · 0 assessment incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: Number of participants with dose-limiting toxicity (DLT) experienced within 49 days (7 weeks) of treatment initiation as assessed by CTCAE v4.0no commentary found | 0 | 0 |
| Secondary endpoint: Number of participants with NeoVax induced IFN γ (interferon γ) T-cell Response against neoepitopes measured by ELISPOT at week 16 | 12 | 10 |
| Secondary endpoint: Number of participants alive at 2 yearsno commentary found | 0 | 0 |
| Population and setting | 12 | 6 |
| The comparisonThe registered arms and what clinicians said about how they compare. | 8 | 5 |
| Safety and tolerability | 6 | 5 |
| Design and conduct | 11 | 7 |
| How clinical authors and accounts interpret adjuvant promise | 30 | 21 |
| Why speakers distinguish neoantigen selection from earlier RCC vaccines | 5 | 3 |
| How speakers explain tumor-directed immune activity | 16 | 5 |
| How accounts weigh personalized manufacture and alternative platforms | 8 | 4 |
| How speakers frame randomized add-on development and sequencing | 9 | 6 |
| How accounts discuss affordability, navigation and patient support | 7 | 2 |
| How accounts connect vaccine promise with research-funding concerns | 8 | 1 |
| How accounts frame therapeutic vaccination and cross-cancer extrapolation | 10 | 3 |
Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.
Sources
115 verified statements from 24 cited sources. A video or podcast is one source but often carries many statements, so the table counts statements, not just posts.
| Channel | Statements | Cited | Screened | |
|---|---|---|---|---|
| Video & audio · 19 statements · 17% | ||||
| YouTube | 19 | 3 | 3 | |
| Posts · 68 statements · 59% | ||||
| X threads | 34 | 14 | 26 | |
| Bluesky threads | 34 | 6 | 8 | |
| Primary sources · 28 statements · 24%cited for context, not screened | ||||
| Publications | 28 | 1 | — | |
Screened: found and read for this trial. Cited: backs at least one statement. Bar = statements; a statement drawn from two sources counts half to each. How we sourced and checked this
max 23 / quarter
- Screened window
- Mar 9, 2019 → Nov 9, 2026
- Cited window
- Aug 25, 2021 → Aug 11, 2026
- Retrieved
- Nov 21, 2026
The trial
from ClinicalTrials.gov- Title
- A Phase I Study Combining NeoVax, a Personalized NeoAntigen Cancer Vaccine, With Ipilimumab to Treat High-risk Renal Cell Carcinoma
- Registry
- NCT02950766
- Study IDs
- 16-097
- Sponsor
- Patrick Ott, MD, PhD
- Collaborators
- Bristol-Myers Squibb, Oncovir, Inc.
- Design
- Phase 1 · Interventional, non randomized, single group
- Status
- Active, not recruiting
- Enrollment
- 19 estimated
- Registered
- 2016-11-01
- Start
- 2019-03-03 actual
- Primary completion
- 2027-12-31 estimated
- Primary endpoint
- Number of participants with dose-limiting toxicity (DLT) experienced within 49 days (7 weeks) of treatment initiation as assessed by CTCAE v4.0
- Interventions
- 2 registered
More on: Renal cell carcinoma, ipilimumab
Scope and limits
This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- 26 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 34 sources about other trials or topics are not included; 2 sources that may describe the trial without naming it were not read; discussion that uses a name the trial shares with other things, without the trial's condition or setting, may be missing.
- The central published experience is small and nonrandomized. It cannot establish comparative efficacy or reliably characterize uncommon harms; the higher local-ipilimumab-dose cohort was not part of the reported analysis.
- The sources reviewed are not a representative sample of HCP practice. Reposts and cross-platform repeats do not add independent judgments, and source-described trial contributors are not external validation.
Show all 9 known gaps +Fewer −
- Clinical roles are not established for several named social accounts, and unidentified spoken passages cannot be assigned to a person from a programme title, description or participant list.
- No separate protocol or NeoVax-specific regulatory label was available in the sources reviewed. This report does not establish regulatory status, reimbursement or routine access.
- Follow-up study descriptions retain their own publication dates and accrual wording. Without a verified shared study identifier, they should not be treated as a single timeline, a change of mind or follow-up efficacy evidence.
- Cross-cancer mRNA comparisons, non-clear-cell applicability, comparative production costs and individual trial eligibility remain unresolved in these sources.
How reports are built and checked: Methods.
Editions and corrections
Last checked for new commentary Nov 21, 2026 UTC. No changes. Follow new editions and changes in this report's change feed (JSON Feed), or the catalog's. How versions and corrections work.
Cite this report
Erudio Health. NCT02950766 (NCT02950766): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 21, 2026. https://www.erudio.com/reports/nct02950766
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "NCT02950766" (NCT02950766), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "nct02950766". If you cannot make requests, read https://www.erudio.com/reports/nct02950766.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email, my organization and the product: the current edition, or 3, 6 or 12 months of updates. Call create_order with report "NCT02950766", that product, email and organization, then show me the quote and the checkout_url to pay by card. If you have a wallet with a payment client for HTTP 402 (MPP with USDC on Tempo, or x402 with USDC on Base) and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id NCT02950766 and sections ["all"], and summarize the findings for me with their sources. The full report can be long: save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/nct02950766.json
curl https://www.erudio.com/reports/nct02950766.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "nct02950766" })release 23d7f463b670502a7f89d581f67590cdb10bcc03879d56b1e64c475fdf153b14
Questions
How much does the NCT02950766 report cost?
One edition costs $750 (Focused · 115 verified statements · 40 from 13 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.
What does the NCT02950766 report cover?
115 statements from 24 sources (3 videos, 20 posts, 1 paper), 40 of them from 13 confirmed clinicians, each linked to its source. Commentary checked Nov 21, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.
Can my AI agent read or buy the NCT02950766 report?
Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "nct02950766" }) previews it and create_order({ "report": "nct02950766", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. Connect your AI client.
How current is the NCT02950766 report?
Edition 1 (version 1.0.0), accepted Nov 21, 2026 UTC; last checked for new commentary Nov 21, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.